证券代码：300026 证券简称：红日药业 编号：2015-001 | --- | --- | --- | |----------------|-------------------------------|-----------------------------------------------------------| | | | | | 投资者关系活动 | √ 特定对象调研 | □ 分析师会议 | | 类别 | □ 媒体采访 | □ 业绩说明会 | | | □ 新闻发布会 | □ 路演活动 | | | □ 现场参观 | | | | □ | 其他 （请文字说明其他活动内容） | | 参与单位名称及 | | 中金公司 陈海刚、国泰君安 胡博新、华创证券 吴晓雯、泰达宏 | | 人员姓名 | 利 庞文杰 、华夏基金 王怡欢等 | | | 时间 | 2015 年 4 月 1 日 | 10：00-12：00 | | 地点 | 中金公司北京会议室 | | | 上市公司接待人 | 董事/总经理 吴玢先生 | | | 员姓名 | 副总经理/董事会秘书 郑丹女士 | | | | 财务负责人 蓝武军先生 | | | 投 ...

证券代码：300026 证券简称：红日药业 编号：2015-003 | --- | --- | --- | |-------------------------|------------------------------|--------------------------------------------------------| | | | | | 投资者关系活动 | √ 特定对象调研 □分析师会议 | | | 类别 | □ 媒体采访 □业绩说明会 | | | | □ 新闻发布会 □路演活动 | | | | □ 现场参观 | | | | □ | 其他 （请文字说明其他活动内容） | | 参与单位名称及 人员姓名 | | 银河证券 李平祝 全铭、华夏基金张钧 代瑞亮 | | 时间 | 2015 年 7 月 1 日 | 14：00-15：00 | | | | | | 地点 | 公司会议室 | | | 上市公司接待人 | 董事长 姚小青先生 | | | 员姓名 | 副总经理/董事会秘书 郑丹女士 | | | 投资者关系活动 | 1 、问：未来三年的规划？ | | | 主要内容介绍 | 姚总： 1 ）配方颗粒 ...

证券代码：300026 证券简称：红日药业 天津红日药业股份有限公司投资者关系活动记录表 编号：2015-002 | --- | --- | --- | |----------------|----------------------------|-----------------------------------------------------------| | | | | | 投资者关系活动 | √ | 特定对象调研 □分析师会议 | | 类别 | □ | 媒体采访 □业绩说明会 | | | □ | 新闻发布会 □路演活动 | | | □ 现场参观 | | | | □ | 其他 （请文字说明其他活动内容） | | 参与单位名称及 | | 华泰证券 姚艺、交银施罗德基金 庄琰、国信证券 李哲霖、浙商 | | 人员姓名 | 证券 王轶、渤海证券 闫芳等 | | | 时间 | 2015 年 6 月 15 | 日 08： 40-09：20 | | 地点 | 公司会议室（电话会议） | | | 上市公司接待人 | 董事长 姚小青先生 | | | 员姓名 | 副总经理 / | 董事会秘书 郑丹女士 | | 投资 ...

证券代码：300026 证券简称：红日药业 天津红日药业股份有限公司 投资者关系活动记录表 编号：2016-001 | --- | --- | --- | |----------------|------------------------------|----------------------------------------------------------| | | | | | 投资者关系活动 | √ | 特定对象调研 □分析师会议 | | 类别 | □ | 媒体采访 □业绩说明会 | | | □ | 新闻发布会 □路演活动 | | | √ 现场参观 | | | | | □其他 （请文字说明其他活动内容） | | 参与单位名称及 | | 华泰证券 姚艺 杨烨辉、银河证券 张金洋、国泰君安 胡博新、 | | 人员姓名 | | 中信证券 刘泽序、中金国际 屠炜颖等 | | 时间 | 2016 年 6 月 24 | 日 10：00-11：00 | | 地点 | | 公司全资子公司天津东方康圣健康管理有限公司会议室 | | 上市公司接待人 | | 董事长 姚小青、总经理 吴玢、副总经理 / 董事会秘书 郑 ...

证券代码：300026 证券简称：红日药业 编号：2020-01 1 天津红日药业股份有限公司投资者关系活动记录表 | --- | --- | --- | |----------------|----------------------------|--------------------------------------------------| | | | | | 投资者关系活动 | □ 特定对象调研 □分析师会议 | | | 类别 | □ 媒体采访 □业绩说明会 | | | | □新闻发布会 □路演活动 | | | | □ 现场参观 | | | | ■ 其他 （电话会议） | | | 参与单位名称及 | 东兴证券 胡博新 王敏杰 | | | 人员姓名 | 中信证券 江辉 | | | | 富安达基金 吴振峰等 | | | 时间 | 2020 年 4 月 29 | | | 地点 | 电话会议 | | | 上市公司接待人 | | 董事、副总经理、董事会秘书、财务负责人 蓝武军 | | 员姓名 | 证券事务代表 商晓梅 | | | 投资者关系活动 | 一、公司介绍 | | | 主要内容介绍 | 1、 2019 ...

证券代码：300026 证券简称：红日药业 编号：2020-03 天津红日药业股份有限公司投资者关系活动记录表 | --- | --- | --- | |----------------|--------------------------------|------------------------------------------------| | | | | | 投资者关系活动 | □ | 特定对象调研 □分析师会议 | | 类别 | □ 媒体采访 □业绩说明会 | | | | □新闻发布会 □路演活动 | | | | ■ 现场参观 | | | | □ 其他 | | | 参与单位名称及 | | 渤海证券 郑翔 姜财义 刘志明 张雄云 马振华 马强 | | 人员姓名 | 国融证券 崔峻 菲徐静 | | | | 中信证券 蔡丽萍 闫勇吕伟 | | | | 大通证券 刘加军 张荷俊 | | | | 长江证券 潘霍喜 | | | | 中银证券 许康 张文光 | | | | 国信证券 姜鹏 许允 孙静 王一晗 | | | | 兴业证券 黄勇 王云鹏 | | | | 国泰君安证券 韩玉玺 范纬华 | | | | ...

证券代码：300026 证券简称：红日药业 编号：2020-02 1 天津红日药业股份有限公司投资者关系活动记录表 | --- | --- | --- | |----------------|------------------------|--------------------------| | | | | | 投资者关系活动 | □ | 特定对象调研 □分析师会议 | | 类别 | □ | 媒体采访 □业绩说明会 | | | □新闻发布会 □路演活动 | | | | □ 现场参观 | | | | ■ 其他 （电话会议） | | | 参与单位名称及 | 东兴证券 胡博新 王敏杰 | | | 人员姓名 | 华夏基金 张帆 | | | | 建信养老金 王新艳 | | | | 人寿养老 张树声 | | | | 天弘基金 郭相博 | | | | 诺安基金 陈勇 | | | | 人保资产 黄鑫 | | | | 东北证券 华锦东 | | | | 国信证券 余方升 | | | | 平安证券 李峰 | | | | 北京新华联产 甄荣军 | | | | 懋石资产 袁一飞 | | | | 渤海汇金 纪钢 | | | --- ...

Financial Performance - The company's revenue for Q3 2022 was ¥1,588,644,754.71, representing a decrease of 20.58% compared to the same period last year[7] - Net profit attributable to shareholders for Q3 2022 was ¥118,289,981.94, down 40.63% year-on-year[7] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥98,572,170.92, a decrease of 50.00% compared to the previous year[7] - Total operating revenue for the third quarter was CNY 4,900,224,293.30, a decrease of 10.67% compared to CNY 5,486,439,217.46 in the same period last year[30] - The net profit for the current period is 469,484,920.92, a decrease of 25.2% compared to 627,306,052.40 in the previous period[32] - The total profit for the current period is 571,274,481.71, down from 766,195,077.14, reflecting a decline of 25.5%[32] - The operating profit for the current period is 542,007,469.41, compared to 754,222,342.94 in the previous period, indicating a decrease of 28.1%[32] - The total comprehensive income for the current period is 489,833,240.84, compared to 629,052,999.17 in the previous period, a decrease of 22.2%[35] - Basic earnings per share for the current period is 0.16, down from 0.21, reflecting a decline of 23.8%[35] Research and Development - R&D expenses for the period amounted to ¥176,091,200, an increase of 52.06% year-on-year, indicating increased investment in research and development[14] - Research and development expenses increased to CNY 176,091,216.83, up from CNY 115,803,855.49, indicating a focus on innovation and new product development[30] Assets and Liabilities - The total assets at the end of the reporting period were ¥11,995,272,284.07, reflecting a growth of 3.34% from the end of the previous year[7] - The total assets reached CNY 11,995,272,284.07, compared to CNY 11,607,300,738.29 in the previous year, showing growth in asset base[29] - Non-current assets totaled CNY 5,111,440,203.53, an increase from CNY 4,801,037,420.21, highlighting investment in long-term assets[29] - The company's total liabilities were CNY 3,676,580,575.85, slightly up from CNY 3,654,921,077.43, indicating stable financial leverage[29] - The equity attributable to shareholders increased to CNY 8,143,563,383.56 from CNY 7,772,888,664.89, reflecting improved profitability and retained earnings[29] Cash Flow - The company's cash flow from operating activities for the year-to-date was ¥252,779,423.82, down 33.83% compared to the same period last year[7] - The cash flow from operating activities for the current period is 252,779,423.82, down from 382,031,160.81, a decline of 33.9%[36] - The cash flow from investing activities shows a net outflow of -508,830,755.94, compared to -397,030,866.12 in the previous period, indicating an increase in outflow[38] - The cash flow from financing activities has a net outflow of -104,473,550.90, contrasting with a net inflow of 566,554,801.03 in the previous period[38] - The total cash and cash equivalents at the end of the period is 956,712,079.30, down from 1,635,365,692.54, a decrease of 41.5%[38] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 138,546, with a total shareholding of 243,820,162 shares pledged[16] - The company reported a total of 305,408,770 restricted shares, with 873,750 shares released during the period[22] - The top shareholder, Chengdu Xingcheng Investment Group Co., Ltd., holds 667,997,417 shares, representing a significant portion of the company's equity[22] - The total number of restricted shares held by the top 10 shareholders remains unchanged at 294,196,979 shares for Yao Xiaoqing[19] Strategic Developments - The company has no new strategies or significant events reported in the third quarter[25] - The company has not reported any new product developments or technological advancements in the latest quarter[25] - There are no mergers or acquisitions mentioned in the third quarter report[25] - The company is exploring market expansion opportunities, although specific strategies were not disclosed in the report[30] - The company maintained a strong cash position, with cash flow metrics to be elaborated in subsequent disclosures, ensuring liquidity for future investments[30] Other Financial Metrics - The weighted average return on equity was 1.46%, down 1.16% from the previous year[7] - The company reported a significant increase in prepayments, which rose by 54.92% year-on-year, indicating higher procurement payments[12] - As of September 30, 2022, the total current assets amounted to CNY 6,883,832,080.54, an increase from CNY 6,806,263,318.08 at the beginning of the year[23] - The cash and cash equivalents decreased to CNY 976,261,663.49 from CNY 1,315,964,613.66 at the beginning of the year[23] - Accounts receivable stood at CNY 3,292,614,423.39, down from CNY 3,506,551,341.00 at the start of the year[23] - Inventory increased to CNY 1,849,163,017.45 from CNY 1,304,511,820.13 at the beginning of the year[23] - The company reported a foreign currency translation difference of 16,990,172.50, compared to -2,510,018.74 in the previous period, indicating a positive change[35]

Financial Performance - The company reported a total revenue of RMB 1.5 billion for the first half of 2022, representing a year-on-year increase of 15%[19] - Net profit attributable to shareholders reached RMB 300 million, up 10% compared to the same period last year[19] - The company has set a revenue target of RMB 3 billion for the full year 2022, indicating a growth forecast of 12%[19] - The company achieved a revenue of 3.312 billion yuan in 2022, a decrease of 5.01% year-on-year[54] - The operating profit for the company was 385 million yuan, down 26.16% compared to the previous year[54] - The total profit amounted to 406 million yuan, reflecting a decline of 23.94% year-on-year[54] - The net profit attributable to shareholders was 352 million yuan, a decrease of 19.56% year-on-year[54] - The company's operating revenue for the reporting period was ¥3,311,579,538.59, a decrease of 5.01% compared to the same period last year[34] - Net profit attributable to shareholders was ¥352,202,610.29, down 19.56% year-on-year[34] - The net profit after deducting non-recurring gains and losses was ¥311,197,919.12, reflecting a decline of 26.72% compared to the previous year[34] Research and Development - The company plans to invest RMB 200 million in R&D for new products and technologies in the upcoming year[19] - Research and development investments increased by 25%, focusing on innovative traditional Chinese medicine products[25] - The company has over 30 ongoing research projects and has submitted more than 5 projects for review by the CDE[48] - The company's R&D investment increased by 26.98% to ¥142,696,420.19, primarily due to improved sales collection[77] - The company is actively pursuing research and development collaborations and overseas investments to introduce advanced wearable health products[67] Market Expansion - User data indicates a growth of 20% in active users of the company's health management services[19] - The company has expanded its market presence by opening 50 new retail locations across various provinces[19] - The company plans to expand its market presence by opening 50 new clinics across China by the end of 2023[25] - The company is exploring potential acquisitions in the healthcare sector to diversify its product portfolio[25] - The company is focusing on enhancing its digital health services to capture a larger market share in the telemedicine sector[19] Product Development - A strategic acquisition of a local pharmaceutical company was completed, enhancing the company's product portfolio[19] - New product launches are expected to contribute an additional CNY 200 million in revenue by Q4 2022[25] - The innovative drug "Xuebijing Injection" has shown a survival rate of 91.7% in severe COVID-19 patients and is included in the National Medical Insurance Drug List[46] - The company has launched a new product, Bopuning (Enoxaparin Sodium Injection), which started nationwide listing work in March[63] - The company has a diverse product portfolio with 28 varieties across 11 categories, including anti-tumor drugs and central nervous system medications, with significant market potential[64] Financial Management - The company will not distribute cash dividends or issue bonus shares for this fiscal year[6] - The net cash flow from operating activities increased by 53.22% to ¥302,646,059.70[34] - The company's cash flow from investment activities increased by 53.22% to ¥302,646,059.70, indicating enhanced investment activities[77] - The inventory increased by 31.84% to ¥1,719,822,700.43, mainly due to an increase in stock of goods and raw materials[82] - The company reported a 44.84% decrease in income tax expenses to ¥57,036,581.68, resulting from reduced tax liabilities during the period[77] Environmental Compliance - The company operates under strict environmental regulations, ensuring compliance with various pollutant discharge standards[144] - The company has updated its pollutant discharge permit as of December 3, 2021, ensuring compliance with environmental regulations[168] - The company has established a comprehensive safety production policy, achieving its safety production goals during the reporting period[172] - The company has developed and revised its environmental self-monitoring plan in accordance with pollutant discharge requirements, ensuring timely completion and public disclosure[169] Corporate Governance - The company fulfilled all commitments made by its controlling shareholders and related parties during the reporting period[179] - There were no non-operating fund occupations by controlling shareholders or related parties during the reporting period[182] - The company did not have any major litigation or arbitration matters during the reporting period[186] - There were no significant related party transactions during the reporting period[188] - The company did not engage in any asset or equity acquisitions or sales during the reporting period[189]

天津红日药业股份有限公司 证券代码：300026 证券简称：红日药业 公告编号：2022-044 天津红日药业股份有限公司 关于参加"2022年度天津辖区上市公司半年报业绩说明会与 投资者网上集体接待日"活动的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、误 导性陈述或重大遗漏。 为进一步加强与投资者的互动交流，天津红日药业股份有限公司（以下简称 "公司"）定于2022年9月6日（星期二）15:00-16:30参加由天津证监局主办、天 津上市公司协会与深圳市全景网络有限公司协办的"2022年度天津辖区上市公司 半年报业绩说明会与投资者网上集体接待日"活动，现将有关事项公告如下： 本次活动将采用网络远程的方式举行，投资者可以登录"全景路演" （http://rs.p5w.net）参与本次互动交流。 出席本次"2022年度天津辖区上市公司半年报业绩说明会与投资者网上集体 接待日"活动的人员有：公司副董事长、董事兼总经理郑丹女士，公司董事、副 总经理、财务负责人兼董事会秘书蓝武军先生。 欢迎广大投资者积极参与。 特此公告。 天津红日药业股份有限公司 董 事 会 二○二二年八月二十九日 ...